14
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Immunization of humans with whole sporozoites confers complete, sterilizing immunity against malaria infection. However, achieving consistent safety while maintaining immunogenicity of whole parasite vaccines remains a formidable challenge. We generated a genetically attenuated Plasmodium falciparum (Pf) malaria parasite by deleting three genes expressed in the pre-erythrocytic stage (Pf p52(-)/p36(-)/sap1(-)). We then tested the safety and immunogenicity of the genetically engineered (Pf GAP3KO) sporozoites in human volunteers. Pf GAP3KO sporozoites were delivered to 10 volunteers using infected mosquito bites with a single exposure consisting of 150 to 200 bites per subject. All subjects remained blood stage-negative and developed inhibitory antibodies to sporozoites. GAP3KO rodent malaria parasites engendered complete, protracted immunity against infectious sporozoite challenge in mice. The results warrant further clinical testing of Pf GAP3KO and its potential development into a vaccine strain.

          Related collections

          Author and article information

          Journal
          Sci Transl Med
          Science translational medicine
          American Association for the Advancement of Science (AAAS)
          1946-6242
          1946-6234
          Jan 04 2017
          : 9
          : 371
          Affiliations
          [1 ] Center for Infectious Disease Research, formerly Seattle Biomedical Research Institute, 307 Westlake Avenue North, Suite 500, Seattle, WA 98109, USA. stefan.kappe@cidresearch.org jkublin@fredhutch.org.
          [2 ] Department of Global Health, University of Washington, Seattle, WA 98195, USA.
          [3 ] Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
          [4 ] Center for Infectious Disease Research, formerly Seattle Biomedical Research Institute, 307 Westlake Avenue North, Suite 500, Seattle, WA 98109, USA.
          [5 ] Department of Laboratory Medicine, University of Washington, 1959 Northeast Pacific Street, NW150, Seattle, WA 98195-7110, USA.
          [6 ] Center for Emerging and Re-emerging Infectious Diseases and Department of Microbiology, University of Washington, 750 Republican Street, E630, Seattle, WA 98109, USA.
          Article
          9/371/eaad9099
          10.1126/scitranslmed.aad9099
          28053159

          Comments

          Malaria vaccine development collection topic 3) Vaccines in development:

          See https://www.scienceopen.com/collection/malariavaccine

          Kublin and collaborators generated a genetically attenuated P. falciparum malaria parasite by deleting three genes expressed in the pre-erythrocytic stage (Pf p52(-)/p36(-)/sap1(-)). They show the results of safety and immunogenicity tests of the genetically engineered (Pf GAP3KO) sporozoites in human volunteers.

          2018-10-08 21:48 UTC
          +1

          Comment on this article